Two new treatments, including therapy blocking a gene mutation occurring in half of melanoma patients, are prolonging lives of people suffering from the deadliest form of skin cancer, clinical trials unveiled Sunday show.
Vemurafenib neutralizes mutation of the key BRAF gene by inhibiting production of a protein which plays a major role in development of melanoma.
Users of the experimental drug were 63 percent less likely to die than people taking chemotherapy, a study showed.
Read more
No comments:
Post a Comment